BIOPICO SYSTEMS Inc. — Department of Health and Human Services SBIR Phase I: 400

Description

Cellular Electrophysiological Purification Array for Preclinical Therapies AbstractReplacement of dead or dysfunctional cardiac myocytes through disruptive cell based therapies has become an emerging and exciting strategy for the treatment of heart failure through organ regenerationHoweverthere are many challenges that should be addressed during the process of cell generation and characterization in preclinical testing as a prelude to clinical testingFor these testshighly viable and functional stem cell derived cardiomyocytes will have greater potential to regenerate and execute extensive repair after myocardial infarctionWith the preliminary results of technical feasibility of a labelfree electrical field potential marker based purification of induced pluripotent stem cells derived cardiomyocytesBiopico systems Inc has increased hope for revolutionary regenerative treatments for heart diseases through preclinical testingIn this Small Business Innovation Research effortBiopico will further develop its `on the fly single cell based electrophysiological sortingandapossystem as a high specific and throughout front end tool to focus on the preclinical clinical marketWith the establishment of an effective functional electrophysiological marker based separation method to isolate differentiated cardiomyocytes exhibiting voltage gated ion channelsa major milestone to sort and validate the cells for preclinical studies will be achievedThe focus of this effort will be to develop a commercial system with optimized and scaled up performanceThis Cellular Electrophysiological Purification Array system will be developed to deploy in preclinical studies that will bring revenues through partnerships and salesTo accomplish this commercializationBiopico Systems Inc has teamed up with academic and industry collaborators for validating the label free cell sorting system for preclinical marketWith the value proposition to sort therapeutic cells at high specificityviability and functionalitythe system will have applications in preclinical testing for patientandapos s safetytherapeutic efficacy and engrafting Project NarrativeThe development of a novel label free high throughput iPSC sorting technology of Biopico systems Inc will contribute to the development of highly innovative tools and technology for analysis of single cellsThe sensitive detection of potentially tumorigenic cells at the single cell level and development of appropriate preclinical immune modelswill permit more effective translation of experimental approaches to human proceduresThis contribution can provide new in vitro models to study disease mechanismsscreening tools for toxicology testingand therapeutic drugs to reverse disease phenotypesOur endeavor to evaluate and optimize preclinical therapies can overcome the barriers that prevent successful translation of advances in regenerative stem cell biology to restoring cardiac function and survivability in the failing heart